
LIXTE Biotechnology's Clinical-Stage PP2A Inhibitor LB-100 Shows Promise in Enhancing Cancer Treatment Efficacy
LIXTE Biotechnology Holdings holds the world's only clinical-stage PP2A inhibitor, LB-100, which enhances cancer cell sensitivity to existing treatments and disrupts cancer repair mechanisms, potentially improving outcomes for patients.
Read full story





















